(6-amino-2-pyridinyl)(1-methyl-4-piperidinyl)-Methanone
[CAS# 613678-03-8]

Identification

• Classification: Organic raw materials >> Heterocyclic compound >> Piperidines
• Name: (6-amino-2-pyridinyl)(1-methyl-4-piperidinyl)-Methanone
• Molecular Formula: C₁₂H₁₇N₃O
• Molecular Weight: 219.28
• CAS Registry Number: 613678-03-8
• SMILES: CN1CCC(CC1)C(=O)C2=NC(=CC=C2)N

Properties

• Solubility: Soluble (19 g/L) (25 ºC), Calc.^*
• Density: 1.153±0.06 g/cm³ (20 ºC 760 Torr), Calc.^*
• Index of Refraction: 1.581, Calc.^*
• Boiling Point: 385.1±42.0 ºC (760 mmHg), Calc.^*
• Flash Point: 186.7±27.9 ºC, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07 Warning
• Hazard Statements: H315-H319
• Precautionary Statements: P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Discovory and Applicatios

(6-amino-2-pyridinyl)(1-methyl-4-piperidinyl)-Methanone is a chemical compound with significant relevance in medicinal chemistry. This substance features a complex structure composed of a pyridine ring, an amine group, and a piperidine derivative, with a methanone functional group that plays a crucial role in its activity. Its discovery and synthesis have been tied to the growing interest in designing molecules capable of interacting with specific biological targets, particularly those involved in neurological and metabolic disorders.

The discovery of (6-amino-2-pyridinyl)(1-methyl-4-piperidinyl)-Methanone is part of the broader field of developing bioactive compounds for pharmaceutical applications. The compound has been studied for its potential as a modulator of neurotransmitter systems. Its structure suggests that it might interact with various receptors or enzymes within the brain, influencing processes such as mood regulation, cognition, and potentially the treatment of neurodegenerative conditions.

One of the key applications of (6-amino-2-pyridinyl)(1-methyl-4-piperidinyl)-Methanone is in drug development for conditions like Parkinson’s disease and other neurodegenerative disorders. The presence of the piperidine moiety makes the compound a potential candidate for influencing dopaminergic signaling pathways, which are central to the pathophysiology of Parkinson’s disease. Additionally, the compound's interaction with other neurotransmitter systems, such as serotonin and acetylcholine, could provide therapeutic benefits in treating cognitive dysfunctions or mood disorders, including depression and anxiety.

The compound also demonstrates potential in broader pharmacological contexts. Its ability to act on a variety of molecular targets makes it useful in screening programs aimed at discovering novel drugs for treating not only neurological diseases but also disorders related to the immune system and cancer. Researchers have continued to investigate its bioavailability, stability, and pharmacokinetic properties to optimize its clinical use. Despite promising results, extensive clinical trials and further studies are necessary to establish the compound's efficacy, safety profile, and optimal therapeutic applications.

In summary, (6-amino-2-pyridinyl)(1-methyl-4-piperidinyl)-Methanone represents an interesting chemical entity in the ongoing exploration of new therapies for neurological and other chronic diseases. Its chemical structure and potential for affecting biological systems position it as a promising candidate for future drug development. As with many compounds in early-stage research, its full therapeutic potential remains to be fully explored through continued experimentation and clinical trials.